Anti-COVID-19 2-DG drug developed by DRDO was first studied by Patanjali, claims Acharya Balkrishna

New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that

has been developed by Defence Research and Development Organization (DRDO)

and been given an emergency use nod by Drugs Controller General of India’s (DCGI),

was first studied by Patanjali researchers, claimed Acharya Balkrishna.

Also Read Story

Milind Deora blames UBT Alliance for Congress’s loss in Maharashtra Elections

Himanta Biswa Sarma supports BJP workers, raises infiltration concerns after Jharkhand defeat

#Jharkhand Election Results| CM Soren credits win to his two sons

#Wayanad Win | Priyanka says 12 hours a day with volunteers, brave ‘Rahul’ helped her victory